Fig. 4.

47-year-old female patient with neuroendocrine liver metastases (pancreatic origin).

Baseline contrast CT (portal venous phase) shows bilobar heterogeneous liver secondary tumours. Target lesions are indicated by black arrows. The patient received sunitinib, a multikinase inhibitor. Two-month follow-up CT (portal venous phase) showed +24% increase in the sum of largest diameters of target lesions, corresponding to progressive disease as per the RECIST 1.1 criteria. Mean target tumour attenuation was a mean −19% lower, corresponding to an objective response according to the Choi criteria. Five-month follow-up CT confirmed the objective response according to the Choi criteria (mean −57% in tumour attenuation) while tumours were considered as stable disease according to RECIST 1.1 (sum of largest diameters of target lesions −8%). RECIST, Response Evaluation Criteria in Solid Tumours.